Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 184 participants.

Also called NCT04327232

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 184 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04327232
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Singapore (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04327232. Randomized; triple masking; primary purpose prevention. Start 2018-05-23 (actual); primary completion 2022-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study
Intervention (Drug)
Spironolactone 25mg
Intervention (Drug)
Placebo oral tablet
Lead sponsor
National University Hospital, Singapore (class: other)
Collaborator
University of Otago (class: other)

Record details

Record id
cardio:ct-nct04327232
Content hash
943499e807feb2ea8c805271e42a022ed7c729c9b8b959044154fab4e4317e34